M Anne Szostak Sells 3,000 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

IDEXX Laboratories Stock Performance

IDXX traded up $2.41 during trading on Thursday, reaching $459.76. 601,058 shares of the company's stock were exchanged, compared to its average volume of 718,152. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The stock has a market capitalization of $37.65 billion, a P/E ratio of 43.09, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company's fifty day simple moving average is $430.12 and its 200-day simple moving average is $453.26.

Analyst Ratings Changes

IDXX has been the subject of a number of recent analyst reports. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth about $412,258,000. International Assets Investment Management LLC raised its stake in shares of IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the last quarter. Flossbach Von Storch SE raised its stake in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after purchasing an additional 464,791 shares during the last quarter. William Blair Investment Management LLC raised its stake in shares of IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after purchasing an additional 369,471 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock worth $179,867,000 after acquiring an additional 316,048 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.